Sinoway Industrial Co., Ltd.

Gliclazide 21187-98-4 Gliclazide 21187-98-4

Gliclazide 21187-98-4
Related Products
  • NanoActive alpha lipoic acid (ALA) 1077-28-7

    1.Basic information of NanoActive alpha lipoic acidProduct Name: NanoActive alpha lipoic acid (ALA)Other Names: NanoActive THIOOCTIC ACIDAppearance: yellow, viscous and transparent liquidTest Method: ...

  • NanoActive Astaxanthin 472-61-7

    1.Basic information of NanoActive AstaxanthinProduct Name: NanoActive AstaxanthinOther Names: NanoActive AstaAppearance: reddish to dark red, viscous and transparent liquidTest Method: HPLCCAS NO.: 47...

  • NanoActive Curcumin 458-37-7

    1.Basic information of NanoActive CurcuminProduct Name: NanoActive CurcuminOther Names: NanoActive turmeric extractAppearance: yellow, viscous and transparent liquidTest Method: HPLCCAS NO.: 458-37-7S...

Basic information of Gliclazide :

Name

Gliclazide

Alias

1-(3-azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea ;1-(hexahydrocyclopenta(c)pyrrol-2(1h)-yl)-3-(p-tolylsulfonyl)-ure ;1-(hexahydrocyclopenta(c)pyrrol-2(1h)-yl)-3-(p-tolylsulfonyl)urea ;benzenesulfonamide,n-(((hexahydrocyclopenta(c)pyrrol-2(1h)-yl)amino)carbonyl ;n-(4-methylbenzenesulfonyl)-n’-(3-azabicyclo(3.3.0)oct-3-yl)urea ;s852 ;se1702

CAS NO.

21187-98-4

Molecular Formula

C15H21N3O3S

Molecular Weight

323.41

Brief Introduction

Gliclazide is a sulfonylurea oral anti-diabetic drug


Use of Gliclazide:

Gliclazide is the second generation oral sulphonylurea hypoglycemic agent, which has a stronger effect. Its mechanism is similar to tolbutamide, that is, it selectively acts on islet β cells, promotes insulin secretion, and improves insulin after glucose intake. freed. Its role is more than 10 times stronger than tolbutamide. In recent years, it has also been found that gliclazide has an extrapancreatic effect, which enhances the effect of peripheral tissues on insulin. It may be the result of enhanced biological effects after insulin receptors. At the same time, hepatic glucose production and output are also resisted, so that gliclazide has a post-pancreatic receptor or receptor. Another view is that sulfonylureas increase the number of insulin receptors in target tissues and increase the sensitivity of peripheral target tissues to insulin. Glieszide has been proven to reduce platelet aggregation and adhesion by animal experiments and clinical use, and prevent the deposition of the albumin on the microvascular wall, which has a preventive and therapeutic effect on diabetic microangiopathy. Animal experiments have shown that long-term use of gliclazide can significantly reduce liver cholesterol, lower triacylglycerols and fatty acids. Histological examinations show that it can resist the damage of arteries, especially coronary arteries, caused by high cholesterol foods, and it is beneficial to reduce the cardiovascular complications of diabetes.

COA of Gliclazide :

Test

Requirement

Result

Appearance

White or almost white powder

White powder

Identification/IR

Corresponding to reference spectrum

Corresponding to reference spectrum

Related  substances

Impurity F

≤0.1%

0.02%


Unspecified impurities

≤0.10%

0.04%


Sum of impurities other than F

≤0.2%

0.04%

Impurity B

≤2ppm

0.4ppm

Heavy metals

≤10ppm

<10ppm

Loss on drying

≤0.25%

0.12%

Sulphated ash

≤0.1%

<0.05%

Assay (dried substance)

99.0~101.0%

99.2%

CONCLUSION

CONFORM WITH BP2017.



  • Rivaroxaban 366789-02-8
    Basic information of Rivaroxaban :NameRivaroxabanAlias(S)-Rivaroxaban;(S)-5-Chloro-N-((2-oxo-3-(4-(3-oxomorpholino)phenyl)-oxazolidin-5-yl)methyl)thiophene-2-carbox;RIVAROXABAN STAGE-IV [5-CHLORO-N-({... Rivaroxaban 366789-02-8
  • Ganciclovir 82410-32-0
    Basic InformationProduct Name: Ganciclovir Synonym: GancyclovirCas No.: 82410-32-0Molecular Formula: C9H13N5O4Molecular Weight: 255.23 Specification: USPUsage: Ganciclovir is an antiviral. It is use... Ganciclovir 82410-32-0
  • Lacosamide 175481-36-4
    Basic information of Lacosamide :NameLacosamideAlias(2R)-2-acetamido-N-benzyl-3-methoxy-propanamide;(2R)-2-(Acetylamino)-3-methoxy-N-(phenylmethyl)propanamide;ADD 243037;Erlosamide;Harkoseride;SPM 927... Lacosamide 175481-36-4
  • Zidovudine 30516-87-1
    Quick DetailsCAS No.:30516-87-1Other Names:AZTMF:C10H13N5O4EINECS No.:n/aPlace of Origin:Fujian, China (Mainland)Type:Anti-aidsGrade Standard:Medicine Grade, Medicine gradeBrand Name:sinowayModel Numb... Zidovudine 30516-87-1

MORE_DETAIL Gliclazide 21187-98-4

Basic information of Gliclazide :

Name

Gliclazide

Alias

1-(3-azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea ;1-(hexahydrocyclopenta(c)pyrrol-2(1h)-yl)-3-(p-tolylsulfonyl)-ure ;1-(hexahydrocyclopenta(c)pyrrol-2(1h)-yl)-3-(p-tolylsulfonyl)urea ;benzenesulfonamide,n-(((hexahydrocyclopenta(c)pyrrol-2(1h)-yl)amino)carbonyl ;n-(4-methylbenzenesulfonyl)-n’-(3-azabicyclo(3.3.0)oct-3-yl)urea ;s852 ;se1702

CAS NO.

21187-98-4

Molecular Formula

C15H21N3O3S

Molecular Weight

323.41

Brief Introduction

Gliclazide is a sulfonylurea oral anti-diabetic drug


Use of Gliclazide:

Gliclazide is the second generation oral sulphonylurea hypoglycemic agent, which has a stronger effect. Its mechanism is similar to tolbutamide, that is, it selectively acts on islet β cells, promotes insulin secretion, and improves insulin after glucose intake. freed. Its role is more than 10 times stronger than tolbutamide. In recent years, it has also been found that gliclazide has an extrapancreatic effect, which enhances the effect of peripheral tissues on insulin. It may be the result of enhanced biological effects after insulin receptors. At the same time, hepatic glucose production and output are also resisted, so that gliclazide has a post-pancreatic receptor or receptor. Another view is that sulfonylureas increase the number of insulin receptors in target tissues and increase the sensitivity of peripheral target tissues to insulin. Glieszide has been proven to reduce platelet aggregation and adhesion by animal experiments and clinical use, and prevent the deposition of the albumin on the microvascular wall, which has a preventive and therapeutic effect on diabetic microangiopathy. Animal experiments have shown that long-term use of gliclazide can significantly reduce liver cholesterol, lower triacylglycerols and fatty acids. Histological examinations show that it can resist the damage of arteries, especially coronary arteries, caused by high cholesterol foods, and it is beneficial to reduce the cardiovascular complications of diabetes.

COA of Gliclazide :

Test

Requirement

Result

Appearance

White or almost white powder

White powder

Identification/IR

Corresponding to reference spectrum

Corresponding to reference spectrum

Related  substances

Impurity F

≤0.1%

0.02%


Unspecified impurities

≤0.10%

0.04%


Sum of impurities other than F

≤0.2%

0.04%

Impurity B

≤2ppm

0.4ppm

Heavy metals

≤10ppm

<10ppm

Loss on drying

≤0.25%

0.12%

Sulphated ash

≤0.1%

<0.05%

Assay (dried substance)

99.0~101.0%

99.2%

CONCLUSION

CONFORM WITH BP2017.


Leave a Message Email Us

we will contact you within 24 hours.

  • TEL:+86-0592-5854962
  • FAX:+86-0592-5854960
  • EMAIL: xie@china-sinoway.com
  • ADDRESS:Floor 16, Huicheng Business Center, No. 839, Xiahe Rd., Siming Dist. Xiamen, Fujian, China
//